anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Carotid Artery Stenosis (CAS) is common in elderly patients undergoing Transcatheter Aortic Valve Replacement (TAVR). However, the impact of CAS on the outcomes of TAVR is unclear.
PURPOSE: This systematic review and meta-analysis aimed to compare the clinical and periprocedural outcomes in patients with and without CAS undergoing TAVR.
METHODS: PubMed, Embase, and Cochrane databases were searched until February 2023. We included studies that performed a direct comparison of outcomes of TAVR in CAS versus non-CAS patients. Data was extracted from published reports and the ROBINS-I tool was utilized for quality assessment. The R studio software (version 4.2.2) was adopted for statistical analysis.
RESULTS: Five observational studies and 111.915 patients were included. The mean age was 80.7 ± 8.2 years and 46.3% were female. The risk of stroke or transient ischemic attack was elevated in the group of patients with CAS (OR 1.44; 95% CI 1.07-1.95; p = 0.016). In contrast, myocardial infarction (OR 1.24; 95% CI 1.05-1.47; p = 0.074) and all-cause mortality (OR 0.99; 95% CI 0.73-1.35; p = 0.95) were not significantly different between CAS and non-CAS groups. Acute kidney injury and new pacemaker implantation did not differ between patients with and without CAS.
CONCLUSIONS: Our findings suggest that CAS is significantly associated with cerebrovascular events in patients undergoing TAVR, without significantly impacting all-cause mortality. Further prospective studies are needed for a more granular assessment of additional determinants of this association, such as unilateral vs. bilateral involvement and whether there is a threshold of CAS severity for increased risk.
The invention belongs to the field of traditional Chinese medicine processing, and specifically relates to a processing process of salted morinda officinalis. The invention aims at solving a technical problem for providing a process flow and key controlling points of a relatively simple method for directly processing salted morinda officinalis. The method comprises the steps that: washing is carried out; salt with a proper amount according to calculation is added; steaming is carried out for 5-7h; core drawing is carried out when the materials are still hot; bake drying is carried out under a low temperature of 55-65 DEG C; and the obtained product is packaged. Key controlling points lie in the washing step and the bake drying step. The invention also provides a salt addition amount controlling method. According to the invention, morinda officinalis yield is measured by sampling, and a proper amount of salt is added according to the ratio, such that an accurate salt content can be obtained. No previous domestic report on the salted morinda officinalis processing process flow and the salt addition amount controlling method is found.
The intervention group received a DVD with low-impact aerobic exercises developed by the researchers in collaboration with a qualified prenatal yoga teacher. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercise program requires twenty minutes to complete. Women were instructed to use the DVD 3 times a week for 3 months.
A mixture, e.g. bath salt, for external application to the human body comprising the soluble salts of sodium, magnesium and at least one further compound comprising the element of potassium, calcium, or phosphorous, wherein the relative quantities of sodium, magnesium, and at least one of potassium, calcium, or phosphorous is between half and twice the recommended daily allowance level. The relative quantities may be measured with regard to weight. The soluble salts may include chlorine and/or sulphur. The soluble salts may include potassium sulphate, sodium chloride, calcium phosphate, and magnesium sulphate (Epson salts). The composition may comprise one or more trace elements. The composition may comprise vitamins, e.g. ascorbic acid or nicotinic acid (niacin).
PURPOSE OF REVIEW: Oscillopsia and unsteadiness are common and highly debilitating symptoms in individuals with bilateral vestibulopathy. A lack of adequate treatment options encouraged the investigation of vestibular implants, which aim to restore vestibular function with motion-modulated electrical stimulation. This review aims to outline the ocular and postural responses that can be evoked with electrical prosthetic stimulation of the semicircular canals and discuss potential approaches to further optimize evoked responses. Particular focus is given to the stimulation paradigm.
RECENT FINDINGS: Feasibility studies in animals paved the way for vestibular implantation in human patients with bilateral vestibulopathy. Recent human trials demonstrated prosthetic electrical stimulation to partially restore vestibular reflexes, enhance dynamic visual acuity, and generate controlled postural responses. To further optimize prosthetic performance, studies predominantly targeted eye responses elicited by the vestibulo-ocular reflex, aiming to minimize misalignments and asymmetries while maximizing the response. Changes of stimulation parameters are shown to hold promise to increase prosthetic efficacy, together with surgical refinements and neuroplastic effects.
SUMMARY: Optimization of the stimulation paradigm, in combination with a more precise electrode placement, holds great potential to enhance the clinical benefit of vestibular implants.
1. Biologically pure Serpens sp. strain HBL-112 ATCC-202005 2. A pharmaceutical composition for preventing and/or treating Papillomatous Digital Dermatitis in ruminants comprising a therapeutically effective amount of Serpens sp. strain HBL-112 ATCC-202005 or S. flexibilis. bacteria or Seroens spp. bacterin and/or an immunologically active portion thereof and/or an antigenic epitope cross-reactive with Serpents spp. and a veterinerally acceptable diluent or a carrier. 3. The composition of claim 2 for treating Papillomatous Digital Dermatitis in ruminants. 4. The composition of claim 2 for prevening Papillomatous Digital Dermatitis in ruminants. 5. The composition of claim 2 comprising Serpents spp. strain HBL-112 or Serpens sps. strain HBL-112 ATCC-202005 bacterin. 6. The composition of claim 2 comprising Serpens flexibilis or SerDens flexibilis bacterin. 7. A method of preventing and/or treating Papillomatous Digital Dermatitis in ruminants comprising administering to the ruminant a therapeutically effective amount of the pharmaceutical composition of any of claims 2 to 6. 8. The method of claim 7, wherein said ruminant has symptoms of Papillomatous Digital Dermatitis. 9. The method of claim 7, wherein said ruminant has no symptoms of Papillomatous Digital Dermatitis 10. A method for determining the presence of PDD antibodies in a sample of ruminant serum comprising contacting said sample with an antigen selected from the group comprising Serpens sp. strain HBL-112 ATCC-202005 or S. flexibilis. bacteria or Seroens spp. bacterin or an immunologically active component and a portion thereof and/or an antigenic epitope cross-reactive with Seroens spp. and detecting antibodies in said sample which bind to said antigen. 11. A method for determining the presence of PDD antibodies in a sample of ruminant serum comprising contacting the sample with an antigen selected from the group comprising Serpens sp. strain HBL-112 ATCC-202005 or an immunologically active component and a portion thereof comprising an antigenic epitope cross-reactive with an antigen Serpens sp. strain HBL-112 ATCC-202005 , adding an anti-ruminant antibody having an enzyme attached, and adding a substrate with which said enzyme can convert to a readily measured product and detecting antigen in said sample 12. A diagnostic kit for use in a method according to claim 11 for determination of the presence of PDD antibodies said kit comprising antigen, conjugate of antibodies to ruminants immunoglobuline and a corresponding substrate. 13. The kit of claim 12 further comprises reagents for sample preparation.
Some biomarkers of acute aortic dissection (AAD) can be used for the potential supplementary diagnosis of AAD, such as C-reactive protein (CRP), smooth muscle myosin heavy chain (SmMHC), and D-dimer (D-D). However, the current measurement methods for common markers primarily rely on sophisticated instruments. The operation process is complicated, and the reagents used are expensive. To provide chronic disease monitoring and home self-examination services for potential AAD patients in real time, we developed a smartphone-based multichannel magnetoelastic (ME) immunosensing device to detect protein levels. Our immunosensor reduced the aforementioned restrictions and demonstrated excellent performance for the supplementary diagnosis of AAD. In this paper, we successfully combined the intelligent terminal with the hardware system to sample the resonance frequency shift (RFS) on the multichannel ME immunosensor. According to the target detection objects with their respective antibodies in the immune binding response, multiple experiments were conducted to detect multiple groups of samples, and we found that a CRP concentration, a SmMHC concentration, and a D-D concentration in the range of 0.1-100μg/mL, 1-4ng/mL, and 0.25-5μg/mL were linearly proportional to the RFS of the ME immunosensor, respectively. For CRP, SmMHC, and D-D, the sensitivities were 13.37Hz/μg∙mL-1, 155.19Hz/ng∙mL-1, and 332.72Hz/μg∙mL-1, respectively, and the detection limits were 2.634×10-3μg/mL, 1.155×10-2ng/mL, and 3.687×10-3μg/mL, respectively. The experiments demonstrated that the accuracy and stability of our device were comparable to those of the vector network analyzer (VNA, Calibration instrument).
Subjects in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers, including analgesic medications. After the 12 week follow up period, patients in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
Denosumab has been considered a treatment option for Central Giant Cell Granuloma (CGCG) a benign locally aggressive osteolytic lesion of the jaws. This study aimed to perform a scoping review of CGCG treated with Denosumab. The research question was: What is Denosumab's effectiveness in treating CGCG of the jaws? Studies that used Denosumab as a treatment for CGCGs in the jaws were selected following PRISMA-ScR guidelines, using Pubmed/Medline, Scopus, and Springer Link databases, among others. Demographics, clinical information, dosing, efficacy, adverse drug reactions (ADRs), and imaging tests used to assess the evolution of the lesions were extracted. Twenty-one studies were selected. Sixty patients with a mean age of 23.2 years were treated with Denosumab, 42% with 120 mg subcutaneously monthly, additional doses on days 1, 8, and 15 for month 1 in adults. In children, dosing was adjusted by weight to 60 or 70 mg. To avoid ADRs 500 mg of calcium and 400 IU of vitamin D orally were used. Initial effective response was reported after 1-3 months, with recurrence of 19.6% and ADRs in 74% of cases. Denosumab is effective for CGCG with monthly subcutaneous doses of 120 mg, 60 or 70 mg in patients < 45 or 50 kg for ≥ 12 months with calcium and vitamin D supplementation until remission changes are observed. Extensive or refractory lesions were the main indications. Common ADRs were hypo and hypercalcemia. Further studies are needed to define dose and supplementation protocols to avoid ADRs during and after therapy.
The importance of ongoing post-discharge follow-up to prevent functional impairment in patients discharged from intensive care units (ICUs) is being increasingly recognized. Therefore, we conducted a scoping review, which included existing ICU follow-up clinic methodologies using the CENTRAL, MEDLINE, and CINAHL databases from their inception to December 2022. Data were examined for country or region, outpatient name, location, opening days, lead profession, eligible patients, timing of the follow-up, and assessment tools. Twelve studies were included in our review. The results obtained revealed that the methods employed by ICU follow-up clinics varied among countries and regions. The names of outpatient follow-up clinics also varied; however, all were located within the facility. These clinics were mainly physician or nurse led; however, pharmacists, physical therapists, neuropsychologists, and social workers were also involved. Some clinics were limited to critically ill patients with sepsis or those requiring ventilation. Ten studies reported the first outpatient visit 1-3 months after discharge. All studies assessed physical function, cognitive function, mental health, and the health-related quality of life. This scoping review revealed that an optimal operating format for ICU follow-up clinics needs to be established according to the categories of critically ill patients.
Sedation with remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min and midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
Background: Physical pain is highly prevalent and impacts the well-being of patients with advanced oncologic disease. Although myofascial pain syndrome (MPS) can be one of the components of pain in cancer patients on palliative care (PC), so far there is no evidence about the benefit of treatment with 1% lidocaine needling. Objectives: To evaluate the efficacy of MPS treatment with injection of 1% lidocaine on the reduction of pain in cancer patients on PC. Design: Single-blind randomized clinical trial. Subjects: Patients aged 50 years or older with end-stage cancer, admitted to a cancer ward or monitored during radiotherapy in three Brazilian hospitals, with a diagnosis of MPS with a pain intensity of five or more according to the Visual Analog Scale (VAS). The patients were divided into two groups: trigger point (TP) injection with 1% lidocaine and control. Measurements: Pain intensity was assessed with the VAS, pain threshold with an algometer, and the medications being used were determined before and 72 hours after the intervention. Results: Thirty patients (15 per group) were assessed. After 72 hours, there was a reduction in referred pain intensity (p < 0.001) and an increase in pressure threshold (p = 0.007) in the intervention group (IG), with no difference in the control. The frequency of individuals who reduced the doses and/or classes of pain medications was higher in the IG (p = 0.011). Conclusion: One percent lidocaine needling in TPs was an effective therapy for pain reduction in MPS.
BACKGROUND: To better assess the risk of distal radial fracture in the general population, we need models that take into account a wide range of risk factors other than osteoporosis. The objective was to develop and validate a model for association of patients' characteristics with distal radial fracture that effectively incorporates multifactorial aspects and includes comorbidities.
METHOD: We analyzed data from a large Longitudinal Health Insurance Database between 2000 and 2013. The outcome of the study was the occurrence of distal radial fracture and the predictors were demographic and comorbidity data. Two machine learning models were developed and validated for patients ≥50 (N = 2745) and <50 (N = 1587) years of age.
RESULTS: For patients aged ≥50 years, selected characteristics included sex, age, urbanization level, osteoarthritis, carpal tunnel syndrome, obesity, hyperlipidemia, trigger finger, hypertension, hypothyroidism, diabetes, hyperthyroidism, and rheumatoid arthritis. For patients <50 years old, selected characteristics included age, sex, diabetes mellitus, urbanization level, carpal tunnel syndrome, hyperlipidemia, osteoarthritis, obesity, and hypertension. Accuracy, sensitivity, specificity, area under the curve, and likelihood ratio were 0.77, 0.83, 0.72, 0.77, and 2.92 for age ≥50 years and 0.73, 0.79, 0.67, 0.73, and 2.41 for age <50 years.
CONCLUSION: The study models can serve as reliable screening tools to assess the risk of distal radial fracture in the general population before bone mineral density testing. In addition, they can be integrated into decision support systems to help healthcare providers identify high-risk patients for additional evaluation and education, ultimately improving the quality of care.
Injectable compositions containing antigenic material comprise a multiple oil/water emulsion in which the continuous phase is aqueous and the primary disperse phase is an oil phase in which an aqueous phase containing antigenic material is dispersed.  Oils may be therapeutically acceptable mineral oils, or vegetable oils such as arachis oil.  The emulsions are prepared by subjecting a mixture of a water-in-oil emulsion having antigenic material in the aqueous phase, an aqueous medium, and an oil-in-water emulsifying agent, to emulsifying conditions; e.g. ultra-sonic vibrations, or treatment in a homogeniser.  The stability of the emulsions may be improved by incorporation of agar in the aqueous component.  Examples are given for the preparation of vaccines for poliomyelitis, pertussis, tetanus, influenza, Newcastle disease, and a multiple vaccine for pertussis, tetanus, diphtheria, poliomyeltitis and measles.
PROBLEM TO BE SOLVED: To obtain the subject agent having an elastase inhibiting activity, keeping the skin taut and elastic of, holding a state of a young skin and useful for e.g. foundation cosmetics, makeup cosmetics, hair cosmetics or bath liquids, by including a solvent extract of Thea sinensis L. SOLUTION: This antiaging agent comprising a solvent extract of Thea sinensis L is obtained by subjecting an extract from the leaves and springs of the above plant to soaking or heat reflux process together with the extract solvent (e.g. methanol, ethanol or 1,3-buthylene glycol), and subjecting it to filtration and concentration. The blending ratio of the extract to the whole agent for external use is 0.001 to 10.0 wt.% based on the dried extract. The antiaging agent may be blended with e.g. a beautifully whitening agent, moisture-retaining agent, antioxidant or oil component. There may be blended e.g. disodium edetate or sodium citrate. The antiaging agent is pref. applied to cosmetics.
A driving circuit of a light emitting diode (LED) includes a rectifier unit, a potential divider circuit, a control unit, a voltage converter, a resistance and a capacitor. The rectifier unit rectifies an AC power to generate a first operation voltage which the potential divider circuit receives to generate a potential divider signal. The control unit includes a regulating unit and a pulse width modulation (PWM) unit. An output terminal of the regulating unit is coupled to the PWM unit which outputs a PWM signal. The voltage converter adjusts a driving voltage and current of a LED. The resistance is coupled between an output terminal of the regulating unit and a diode. The capacitor is coupled between a power input terminal of the regulating unit and a ground terminal. The PWM unit adjusts the PWM signal according to the potential divider signal and a feedback signal output by the voltage converter.
NEW MATERIAL:The compound of formula I. USE:A tuberculostat. It exhibits strong growth inhibiting activity against Mycobacterium tuberculosis, and extremely strong bactericidal effect even to the bacteria of resting stage. It is transferred readily to the pulmonary tissue which is a tissue liable to be attached by tubercursos, by oral administration. It has low toxicity. PREPARATION:The objective compound can be prepared according to the reac tion formula, by reacting the 3-halogenorifamycin S of formula II (X is halogen) (a starting material) with 3-amino-pyridine-2-thiol of formula III in a polar organic solvent such as formamide, preferably in the presence of a basic sub stance such as sodium bicarbonate, usually at 0-40 deg.C, preferably treating the reaction product with an oxidizing agent such as manganese dioxide to obtain the pyridothiazinorifamycin of formula IV, and reacting the compound with N-ethylisopropylamine of formula V in a polar solvent such as DMF, usually at 0-40 deg.C for 10hr-10 days.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to compounds of the general formula (I) α where one of X and Y means C= O and another means C= O or  ; among CH 2  one means R 1 , R 2 , R 3 , R 4  and others mean hydrogen atom; -NHR 5  mean hydrogen atom or alkyl under condition that R 5 , R 6  is not hydrogen atom if X and Y are C= O and one of R 6  means amino-group. New compounds of the formula (I) show property to inhibit tumor necrosis factor R 1 , R 2 , R 3 , R 4  and therefore they can be used in pharmaceutical composition as an active component. Also, compounds of the formula (I) can be used in method for decrease of unfavorable levels of tumor necrosis factor--α in mammals. EFFECT: valuable medicinal properties of compounds and composition. 8 cl, 1 tbl, 37 ex
BACKGROUND: Toxoplasma gondii is an intracellular protozoan parasite that is widely distributed in humans and warm-blooded animals. T. gondii chronic infections can cause toxoplasmic encephalopathy, adverse pregnancy, and male reproductive disorders. In male reproduction, the main function of the testis is to provide a stable place for spermatogenesis and immunological protection. The disorders affecting testis tissue encompass abnormalities in the germ cell cycle, spermatogenic retardation, or complete cessation of sperm development. However, the mechanisms of interaction between T. gondii and the reproductive system is unclear. The aims were to study the expression levels of genes related to spermatogenesis, following T. gondii infection, in mouse testicular tissue.
METHODS: RNA-seq sequencing was carried out on mouse testicular tissues from mice infected or uninfected with the T. gondii type II Prugniaud (PRU) strain and validated in combination with real-time quantitative PCR and immunofluorescence assays.
RESULTS: The results showed that there were 250 significant differentially expressed genes (DEGs) (P < 0.05, |log2fold change| ≧ 1). Bioinformatics analysis showed that 101 DEGs were annotated to the 1696 gene ontology (GO) term. While there was a higher number of DEGs in the biological process classification as a whole, the GO enrichment revealed a significant presence of DEGs in the cellular component classification. The Arhgap18 and Syne1 genes undergo regulatory changes following T. gondii infection, and both were involved in shaping the cytoskeleton of the blood-testis barrier (BTB). The number of DEGs enriched in the MAPK signaling pathway, the ERK1/2 signaling pathway, and the JNK signaling pathway were significant. The PTGDS gene is located in the Arachidonic acid metabolism pathway, which plays an important role in the formation and maintenance of BTB in the testis. The expression of PTGDS is downregulated subsequent to T. gondii infection, potentially exerting deleterious effects on the integrity of the BTB and the spermatogenic microenvironment within the testes.
CONCLUSIONS: Overall, our research provides in-depth insights into how chronic T. gondii infection might affect testicular tissue and potentially impact male fertility. These findings offer a new perspective on the impact of T. gondii infection on the male reproductive system.